323 related articles for article (PubMed ID: 27039982)
1. Engineering virus-like particles as vaccine platforms.
Frietze KM; Peabody DS; Chackerian B
Curr Opin Virol; 2016 Jun; 18():44-9. PubMed ID: 27039982
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
3. Integrated molecular and bioprocess engineering for bacterially produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen.
Tekewe A; Fan Y; Tan E; Middelberg AP; Lua LH
Biotechnol Bioeng; 2017 Feb; 114(2):397-406. PubMed ID: 27497268
[TBL] [Abstract][Full Text] [Related]
4. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
Engeroff P; Bachmann MF
Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particle-based vaccines against hepatitis C virus infection.
Bellier B; Klatzmann D
Expert Rev Vaccines; 2013 Feb; 12(2):143-54. PubMed ID: 23414406
[TBL] [Abstract][Full Text] [Related]
6. Synthetic biology design to display an 18 kDa rotavirus large antigen on a modular virus-like particle.
Lua LH; Fan Y; Chang C; Connors NK; Middelberg AP
Vaccine; 2015 Nov; 33(44):5937-44. PubMed ID: 26387437
[TBL] [Abstract][Full Text] [Related]
7. Porcine parvovirus capsid protein expressed in Escherichia coli self-assembles into virus-like particles with high immunogenicity in mice and guinea pigs.
Ji P; Liu Y; Chen Y; Wang A; Jiang D; Zhao B; Wang J; Chai S; Zhou E; Zhang G
Antiviral Res; 2017 Mar; 139():146-152. PubMed ID: 28063996
[TBL] [Abstract][Full Text] [Related]
8. Synthetic biology for bioengineering virus-like particle vaccines.
Charlton Hume HK; Vidigal J; Carrondo MJT; Middelberg APJ; Roldão A; Lua LHL
Biotechnol Bioeng; 2019 Apr; 116(4):919-935. PubMed ID: 30597533
[TBL] [Abstract][Full Text] [Related]
9. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
10. Multi-antigen avian influenza a (H7N9) virus-like particles: particulate characterizations and immunogenicity evaluation in murine and avian models.
Hu CJ; Chien CY; Liu MT; Fang ZS; Chang SY; Juang RH; Chang SC; Chen HW
BMC Biotechnol; 2017 Jan; 17(1):2. PubMed ID: 28061848
[TBL] [Abstract][Full Text] [Related]
11. Production of Virus-Like Particles for Vaccination.
Thompson CM; Aucoin MG; Kamen AA
Methods Mol Biol; 2016; 1350():299-315. PubMed ID: 26820864
[TBL] [Abstract][Full Text] [Related]
12. Enveloped virus-like particle platforms: vaccines of the future?
Pitoiset F; Vazquez T; Bellier B
Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245
[TBL] [Abstract][Full Text] [Related]
13. Prokaryotic Production of Virus-Like Particle Vaccine of Betanodavirus.
Xie J; Huang R; Lai Y
Methods Mol Biol; 2016; 1404():211-223. PubMed ID: 27076301
[TBL] [Abstract][Full Text] [Related]
14. Plant Virus Nanoparticles for Vaccine Applications.
Santoni M; Zampieri R; Avesani L
Curr Protein Pept Sci; 2020; 21(4):344-356. PubMed ID: 32048964
[TBL] [Abstract][Full Text] [Related]
15. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines.
Lei X; Cai X; Yang Y
Expert Rev Vaccines; 2020 Mar; 19(3):235-246. PubMed ID: 32133886
[No Abstract] [Full Text] [Related]
17. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
18. Peptide presentation on primate erythroparvovirus 1 virus-like particles: In vitro assembly, stability and immunological properties.
Del Carmen Morán-García A; Rivera-Toledo E; Echeverría O; Vázquez-Nin G; Gómez B; Bustos-Jaimes I
Virus Res; 2016 Sep; 224():12-8. PubMed ID: 27523978
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.
Shoji Y; Prokhnevsky A; Leffet B; Vetter N; Tottey S; Satinover S; Musiychuk K; Shamloul M; Norikane J; Jones RM; Chichester JA; Green BJ; Streatfield SJ; Yusibov V
Hum Vaccin Immunother; 2015; 11(1):118-23. PubMed ID: 25483524
[TBL] [Abstract][Full Text] [Related]
20. Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease.
Azevedo MP; Vlasova AN; Saif LJ
Expert Rev Vaccines; 2013 Feb; 12(2):169-81. PubMed ID: 23414408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
